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Apolipoprotein  B  (apoB) is a  large  glycoprotein that 
circulates in plasma as a major constituent of  numerous 
lipoproteins. ApoB exists in two forms: apoB48 and 
apoB100.  ApoB48 is identical in sequence to the N-ter- 
minal region of apoBlOO and is generated by sequence- 
specific mRNA editing of the apoBlOO transcript.  Here, 
we  describe the development of a line of  mice expressing 
a  human  apoB  transgene  driven by promoterlenhancer 
sequences from the transthyretin gene. In these mice, 
immunodetectable  human apoBlOO is synthesized by the 
liver,  kidney,  and  brain. Human  apoBlOO is found in low 
concentration (-0.1 mg/dl) in the plasma of the trans- 
genic mice  and circulates in the low density lipoprotein 
fraction. The hepatic human apoBlOO transcripts un- 
dergo mRNA editing at only slightly lower efficiency 
than the endogenous mouse apoBlOO message. There- 
fore, there is no absolute species specificity to the 
apoBlOO  mRNA editing process. 
Apolipoprotein B (apoB)l  is a major  integral  component of 
numerous  lipoproteins and is essential for  both the synthesis of 
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triglyceride-rich  lipoproteins  and the catabolism of cholesterol 
ester-rich particles. ApoB exists in two forms: apoBlOO and 
apoB48. In humans, apoBlOO is  synthesized  almost  exclusively 
in the  liver  and  is  required  for  the  formation  and  secretion of 
triglyceride-rich  very low density  lipoproteins  (1). ApoBlOO is 
the only  apolipoprotein in low density  lipoprotein  (LDL),  the 
major vehicle for cholesterol-ester  transport  in  humans,  and 
sequences within its C-terminal region mediate clearance of 
LDL in  tissues  by the LDL receptor (2). The other  form of apoB, 
apoB48,  is  made  in human small  intestine  and  is  necessary  for 
the  packaging of dietary lipids into chylomicrons. ApoB48 is 
identical  to the N-terminal-48% of the apoBlOO protein  and so 
does  not  contain  the  C-terminal  sequences  required  for LDL- 
receptor  binding (3). 
Both apoBlOO and apoB48 are products of the same gene (3, 
4). In the intestine, a post-transcriptional  modification of 
apoBlOO mRNA results in  a substitution of uridine  for  cytosine 
at nucleotide 6666. The likely  mechanism  responsible  for this 
event is a site-specific cytosine deamination of the apoBlOO 
mRNA (3-6). Evidence  suggests that multiple  proteins  partici- 
pate in this RNA editing event, and recently a 229-residue 
protein that is   par t  of this  complex has been  purified  and cloned 
(7-9). 
There are important  species  differences in the  proportion of 
apoBlOO RNA that is  edited in liver  and  intestines.  Based  on 
the  relative  amounts of apoBlOO and  apoB48 in human  liver 
and intestine, it has been estimated that less than 1% of 
apoBlOO mRNA is edited  in the liver  and >95% is  edited in the 
intestine (10). In contrast,  in  both rats and mice, a variable 
percentage of the apoBlOO mRNA is  edited in the liver  depend- 
ing  on the hormonal,  nutritional, and developmental  status of 
the animal (11-16). It has been suggested that there is not 
necessarily  species  specificity  to the mRNA  editing  process in 
vivo (1, 17). 
In  this  paper  we  describe  the  development of a line of trans- 
genic  mice  expressing a human apoBlOO minigene  driven  by 
the  mouse  transthyretin  promoter.  Despite low levels of 
apoBlOO expression, these mice  edit the human apoBlOO 
mRNA with only a slightly  decreased efficiency when  compared 
to  the  mouse apoBlOO transcript. 
MATERIALS AND METHODS 
Development of Human ApoBlOO Dansgenic Mice-A human 
apoBlOO expression construct (pITR-Bl00 (Leu-Leu), where TTR is 
transthyretin) was made using enhancedpromoter sequences from the 
mouse transthyretin gene (18, 191, exons 1-26 of the human apoBlOO 
cDNA, and the  last three exons and introns from the human apoB gene, 
including 2.3  kb of the 3’-untranslated region. A pGEM3 vector contain- 
ing  a 290-base pair fragment from the distal mouse transthyretin en- 
hancer (-2.15 to -1.86 kb) fused to the promoter element (-1 to -202) 
was kindly provided by Dr. R. H. Costa, University of Chicago,  Chicago, 
IL. An EcoRI(blunt-ended)iPstI fragment from pGEM3 was inserted 
into pBSK31I (pBIueScript I1 SKS, Stratagene), which had been di- 
gested with SmaI and PstI to  generate pBSKSII-TTR2. An EcoRI frag 
ment extending from  nucleotide  17  to  6507 and encoding the N-terminal 
46% of apoBlOO from the apoB53 cDNA (20) was  subcloned into the 
EcoRI site  in  the polylinker of pBSK SII-TTR2 to generate pBSKSII- 
To synthesize a full-length apoBlOO construct, a SpeI-CEaI fragment 
encompassing the TTR enhancer/promoter elements plus the coding 
sequences for apoB42 (from pBSKII-TTR-B46) was inserted into the 
expression vector pBlOO (Leu-Leu).2 This human apoBlOO expression 
TTR-B46. 
Z. Yao, unpublished obsewation. 
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construct had been modified by site-directed mutagenesis to change 
codon 2153  from CAA (Gln)  to CTA (Leu).  Neither  the  edited  (UUA)  nor 
unedited (CUA) transcript  terminates  translation at this position, so no 
apoB48 is  made  (21).  A  18.3-kb  SpeI-KpnI  fragment  was  purified  from 
pTTR-B100 (Leu-Leu)  injected  into  fertilized C57BV6 x SJL F, hybrid 
mice eggs. Mice containing  the  transgene  were  identified by dot blot 
hybridization of genomic DNA extracted from tail homogenate. One 
male  mouse  (578-7)  expressed  the  transgene,  and a line  was  established 
by breeding  with C57BV6 x SJL F1 females. 
Immunoblot Analysis of ApoBlOO Synthesis in 'Dansgenic Mice 
-Mice were  anesthetized  using an  intraperitoneal injection of 90  mgikg 
sodium pentobarbital and perfused with phosphate-buffered saline 
(PBS).  Tissues  were collected and cell homogenates  were  made as pre- 
viously described  (22).  A  total of 12  mg of protein from each  tissue  were 
subjected  to  immunoprecipitation  using  30  pg of a rabbit  anti-human 
apoBlOO polyclonal antibody.  The  immune complexes were recovered 
using 100 pl of Sepharose G beads, and washes were performed as 
described (23). The immunoprecipitates were redissolved in 20 pl of 
PBS  and 20 pl of loading  buffer (20% (v/v) glycerol, 4.6% (w/v)  SDS,  125 
mM Tris-C1, pH  6.8, 0.15% (w/v) bromphenol  blue,  5% (v/v) p-mercapto- 
ethanol). After boiling for  5  min,  a 20-111 aliquot  was  loaded  onto  a 5% 
SDS-polyacrylamide  gel  and  electrophoresis  was  performed for 1 h and 
30  min a t  150 V, 4 "C. The  proteins  were  transferred  and  immunoblot- 
ted  as described  (22)  using  a monoclonal antibody  against  the  N-termi- 
nal region of human apoBlOO (MB3) (24,  25) a t  a  dilution of 1:lOOO 
followed by incubation  with  a  sheep  anti-mouse  horseradish  peroxidase- 
conjugated  antibody  (Amersham Corp.). The filter  was developed using 
the ECL  Western  blotting  detection  kit  (Amersham  Corp.)  and exposed 
to XAR-5 film (Kodak). 
Quantification of Plasma  Human ApoBlOO Levels in Mouse Plasma 
-The human apoBlOO concentrations  in  the  mouse  plasma  were de- 
termined  using a solid  phase  radioimmunoassay. Ninety-six-well flex- 
ible polyvinyl chloride  microliter  plates  were  coated for 3 h with  PBS 
containing  2 pg/ml MB47, an  immunopurified human apoB100-specific 
antibody (24); which binds apoBlOO near amino acid residue 3500. 
Subsequently, the microliter  plates  were  incubated  with  PBS  contain- 
ing 20 mg/ml radioimmunoassay  grade bovine serum  albumin (BSA) 
(Sigma) for 45 min.  A  total of 1-2 p1 of mouse  plasma  was  added  to 
each well and incubated overnight at 4 "C. The plates were then 
washed  six  times  with  PBS  containing 0.1% (w/v) BSA and 0.05% (v/v) 
Tween 20. Then,  50 pl of 12"I-labeled human apoB-specific monoclonal 
antibody, C1.4 (-10,000 cpdng) ,  was added to each well (400,000 
cpdwell). Antibody C1.4 (generously provided by Dr. Elaine Krul, 
Washington  University, St. Louis, MO) binds apoBlOO near  amino  acid 
500 (25).  The  plates  were  then  incubated  with  the 12sI-C1.4 for 6 h and 
washed as previously described, and radioactivity was quantitated. 
The  standard  curve  was  generated  using  purified  human LDL (26) di- 
luted in a PBS solution that contained 20 mg/ml BSA, 0.05% (v/v) 
Tween 20, and 0.04% (w/v)  NaN3.  The  standard  curve  ranged  from  0.3 
ng  to  2.048  pg  per well. 
Analysis of Distribution of Human ApoBlOO Distribution  in  'Dans- 
genic Mice Plasma-A total of 100 pl of plasma from a human,  an 
apoBlOO transgenic  mouse,  and  a  control  littermate  was  adjusted  to a 
density of 1.215 g/ml with KBr. Ultracentrifugation  was  performed for 
11 h a t  4 "C using  a  Beckman TLA-100 rotor at  436,000 x g. Aliquots of 
10 pl from the  top  and  bottom  fractions  were  added  to  10 p1 of loading 
buffer  (see above), boiled for 5 min,  and  loaded onto a 5% SDS-poly- 
acrylamide  gel. The human  sample  was  diluted 1:lOO in PBS prior  to 
electrophoresis. Electrophoresis, transfer, and immunoblotting were 
performed  exactly as described above. 
Plasma  from  three  human apoBlOO transgenic mice (500 pl) was 
adjusted  to  a  density of 1.215 g/ml with KBr and subjected  to  ultracen- 
trifugation at 240,000 x g for 44 h at 4 "C using a Beckman Ti-50.3 rotor. 
The  lipoprotein  fraction  was  adjusted  to a volume of 3 ml  using 0.15 M 
NaC1, 0.01% (wh)  Naz EDTA, 0.02% (w/v) NaN, at pH 7.2. A 2-ml 
aliquot  was  subjected  to  gel  filtration a  Superose  6B  column  using a 
fast  protein  liquid  chromatography  (FPLC)  apparatus  (27).  Fractions of 
2  ml  were collected, and 200 p1 from  each  fraction  was  used  to  measure 
the cholesterol content with an  enzymatic calorimetric assay (Boeh- 
ringer  Mannheim).  Every  three  fractions  were pooled and  subjected  to 
trichloroacetic acid precipitation as  described  (27).  The  pellet  was  solu- 
bilized in  the loading  buffer  (see above), boiled for 5 min,  and  loaded 
onto  a 5% polyacrylamide  gel  containing  SDS. After electrophoresis, the 
proteins were transferred and immunoblotting was performed using 
MB3, as described above. 
Analysis of 'Dansgenic Liver RNA-Total liver  and  small  intestinal 
RNA from three  transgenic  and  three  control mice were  isolated  (28) 
and  diluted  to  1.0 pg/pl. l b o  pg of each  RNAsample  was  amplified  with 
either  mouse- or human-specific  primers  and  2  units of Ret.rothermTM 
RT polymerase (Epicentre Technologies, Madison, WI) using buffers 
supplied by the  manufacturer. Two oppositely oriented  human-specific 
oligonucleotides, M49 (5'-CTG AAT TCA TTC AAT TGG GAG  AGA  CAA 
GTT TCA A-3') and M50 (5'-CGG ATA TGA TAG TGC TCA  TCA AGA 
C-3'),  were employed to  amplify a 278-base  pair  fragment  extending 
from  nucleotide  6506  to  6784 of human apoB100. The  corresponding 
region of the mouse apoBlOO  RNA was  amplified  using mouse-specific 
oligonucleotides, M49R (5'-CGG AAT TCA TCT GAC TGG GAG AGA 
CAA GTA CGT G 3') and M5Omus (5'-CGG ATA TGA TAC TGT TCA 
TCA AGA A-3'). After amplification, the reaction products were ex- 
tracted  with  phenol  and chloroform (l:l),  passed  over  a  Chromaspin- 
100  column  (Clontech  Laboratories,  Inc.,  Palo Alto, CA) to remove free 
nucleotides,  and  precipitated  with  three  volumes of ethanol.  The PCR 
products  were  resuspended  in  TE  (10 mM Tris, 1 mM Naz EDTA, pH 8) 
and subjected  to  primer  extension  analysis as described (5). The  extent 
of editing  was  determined by scanning the  primer  extension  gels  with 
an Ambis-100 radioactive  imaging  system. 
RESULTS AND DISCUSSION 
A human (apoB100) fragment driven by the  transthyretin 
enhancer/promoter element (Fig. 1) was microinjected into 725 
fertilized C57BV6 x SJL Fz hybrid eggs. The eggs  were trans- 
ferred into pseudopregnant females, and 34% (29 mice) of the 
86 offspring contained the human apoBlOO transgene, as  as- 
sessed by dot blot hybridization of total nucleic acids. A 10-pl 
aliquot of plasma from each transgenic mouse was subjected to 
immunoblotting, and a single male mouse had detectable 
amounts of human apoBlOO (data not shown). The copy num- 
ber of the transgene  in  the offspring of this founder was esti- 
mated to be  20  by quantitative genomic blotting. 
To determine the tissue distribution of expression of human 
apoB100, tissue homogenates were subjected to immunoblot- 
ting using MB3, a human-specific anti-apoB100 mouse mono- 
clonal antibody that binds near apoBlOO amino acid residue 
1000 (29). ApoBlOO protein expression was not detectable using 
standard immunoblotting techniques. Therefore, immunopre- 
cipitation studies were performed on tissue  extracts from ani- 
mals, which had been perfused extensively with PBS prior to 
organ removal. Immunoreactive material of the expected size 
was identified in liver and brain and in trace  amounts in the 
kidney (Fig. 2). Previously, a  similar promoter/enhancer con- 
struct from the TTR gene was shown to result in liver-specific 
expression (18). However,  mice with high copy numbers of this 
promoter element also expressed TTR in  brain and kidney (30). 
The antibody employed for immunoprecipitation detection, 
MB3, also recognizes  apoB48 (29). No human apoB48 protein 
was identified in any of the tissue samples. This was the ex- 
pected result, since the construct used to make the transgenic 
mice was engineered to preclude the formation of apoB48. The 
construct contained a  substitution of a thymidine for adenine in 
the second  position of  codon 2153  from CAA (Gln) to CTA (Leu). 
Message editing would not effect the amino acid  encoded, since 
the edited transcript (UUA) also encodes a leucine residue. 
Importantly, this base pair substitution has been previously 
J-5 CAA + + CTA 
Y 
1 kb 
T r R  Enhancer + Promoter 
vector (pTTR-B100 (Leu-Leu)) contains enhancer-promoter elements 
FIG. 1. Human apoBlOO expression construct. The expression 
from the mouse  transthyretin  gene  (striped box), the coding region of 
the  human apoBlOO  cDNA (solid boxes), the  last  three  introns of the 
apoBlOO gene  (white boxes), and  2.3  kb of the  3'-untranslated region 
(cross-hatched boxes). Site-directed  mutagenesis  was  performed at   the  
site  at which the apoBlOO mRNA is edited (CAA - CTA) to prevent 
apoB48  synthesis. 
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FIG. 2. Tissue distribution of human apoBl00 protein expres- 
sion. Twelve mg of total  protein from tissue  homogenate  were  subjected 
to immunoprecipitation  using  a  rabbit  anti-human apoBlOO polyclonal 
antibody as described  under  “Materials  and Methods.” The  precipitate 
was  size-fractionated on a  5%  SDS-polyacrylamide gel under  reducing 
conditions,  transferred  to  nitrocellulose,  and  incubated  with  a  mouse 
anti-human apoBlOO antibody  (MB3)  and  then  with a sheep  anti-mouse 
IgG that  was conjugated  to  horseradish  peroxidase (HRPO). The mem- 
brane  was exposed to XAR-5 film for 30 s (plasma  samples)  and 3 min 
(tissue  samples)  prior  to developing. 
demonstrated in vitro not to  interfere significantly  with 
apoBlOO  mRNA editing (21). 
The  plasma levels of  apoBlOO were quantitated  using a sen- 
sitive  sandwich  radioimmunoassay. The concentrations of 
apoBlOO in the F, apoBlOO mice ranged from 0.035 to 0.10 
mg/dl with a mean level of 0.07 mg/dl. It  is likely that  the low 
level of human apoBlOO expression is  due to the fact that  the 
construct does not contain all of the gene-specific sequences 
necessary for high levels of  apoBlOO expression. Though all the 
cis-acting  sequences  necessary for apoBlOO transcription  have 
not yet been characterized, an  enhancer  element  has been iden- 
tified in  intron 2 of the  human apoBlOO gene and  these se- 
quences are not included in the  human apoBlOO transgene (31, 
32). 
The  total cholesterol (mg/dl) (74.2 * 10.5 (transgenic) versus 
79.6 * 2.8 (control)) and triglyceride levels (mg/dl) (87.5 * 4.7 
(trangenic) uersus 129.8 * 15.2 (control) were similar in five 
apoBlOO transgenic mice and  their  littermate controls. To de- 
termine if the apoBlOO expressed  in the  plasma  was associated 
with lipoproteins, aliquots of plasma from human, a control, 
and a transgenic mouse were subjected to ultracentrifugation 
at a density of 1.215 g/ml. Aliquots from the top (d < 1.215 g/ml) 
and bottom (d > 1.215 g/ml) fractions  were  size-fractionated on 
a 5% reduced SDS-polyacrylamide gel and immunoblotted with 
a human apoB-specific monoclonal antibody  (MB3)  (Fig. 3A, top 
panel ). All the immunoreactive material  was  present  in  the top 
fraction of the mouse sample, so the  human apoBlOO circulates 
as  part of a lipoprotein in the mouse. 
To determine  the  distribution of human apoBlOO in the lipo- 
proteins, FPLC was performed using  plasma pooled from five 
transgenic  and five control mice. The lipoprotein profiles were 
identical in  the control and  transgenic mouse plasma (control 
data not  shown). In  the  transgenic mice, the apoB immunore- 
active material  was localized to fractions 12-18, which corre- 
sponds to  the LDL peak (Fig. 3B).  
Next we determined  whether  the full-length human apoBlOO 
transcript  underwent mRNA editing. Because the levels of hu- 
man apoBlOO  mRNA in the livers of the  transgenic mice were 
very low, the reverse transcriptase-polymerase  chain reaction 
(RT-PCR) was used to amplify a 278-base pair  fragment from 
the liver transgene apoB mRNA in  the vicinity of the  editing 
site  (base  pairs 6506-6784) from total  hepatic mouse mRNA. 
The RT-PCR amplification of the liver mRNA from the  trans- 
genic mice, but not from the non-transgenic littermates, pro- 
duced DNA fragments of the appropriate size (Fig. 4A). A 
primer-extension assay on the PCR amplification  products of 
the  human apoBlOO  mRNA isolated from transgenic livers re- 
vealed that  the  human apoBlOO mRNAwas  edited (Fig. @). To 
A. nmm 
Human  Co trol Mouse 
T B T  B T  B 
% 
r‘ 200- 
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FIG. 3. Distribution of human apoBlOO in transgenic mice 
plasma. A total of 100 pl of plasma from a  human, control mouse, and 
transgenic mouse were  subjected  to  ultracentrifugation a t  density 1.215 
g/ml. Aliquots of the top ( T )  and bottom ( B )  fractions  were loaded onto 
a  5%  SDS-polyacrylamide gel under  reducing conditions. After transfer 
to  nitrocellulose, the  proteins  were  immunoblotted  using  a mouse mono- 
clonal anti-human apoBlOO antibody  (MB3) as  described under  “Mate- 
rials  and Methods.” The  membrane  was exposed to XAR-5 film for 2 min 
(panel A) .  A  total of 500 pl of plasma  was pooled from five apoBlOO 
transgenic mice and  subjected  to  ultracentrifugation a t  d = 1.215 g/ml. 
A 2-ml aliquot of the top  fraction (d  < 1.215 g/ml)  was  subjected  to gel 
filtration  using  a  Superose 6B column and  an FPLC  apparatus. Two 
milliliter  fractions  were collected and  the  total cholesterol content  was 
measured  in  each  fraction.  Every  three  fractions  were pooled, and  the 
proteins were precipitated using 15% trichloroacetic acid (v/v). The 
pellets  were  washed  and  resuspended  in 40 pl of loading buffer, and  15 
pl were  size-fractionated  onto  a 5% polyacrylamide gel containing  SDS 
under  reducing conditions. Immunoblotting wati performed using MB3, 
and  the  filter  was exposed to film for 4 min  prior to developing. 
compare the efficiency of editing of the human and mouse 
apoBlOO mRNA, mouse-specific oligonucleotides were em- 
ployed to amplify the corresponding fragment from the mouse 
apoBlOO mRNA. The  human apoBlOO mRNA transcript was 
edited  with a somewhat lower efficiency than  the endogenous 
mouse liver apoBlOO transcript (Fig. 10. The observed reduc- 
tion in the efficiency of editing of the  human apoBlOO tran- 
script  cannot be attributed  to  the “Leu-Leu” mutation since a 
synthetic 354-nucleotide apoB RNA substrate that included 
this  mutation  was edited in vitro as effectively (7.8%) as  the 
wild-type human sequence (6.0%) using a rabbit enterocyte 
editing  extract  (data not  shown). Admittedly, the level of ex- 
pression of human apoB in our  transgenic mice is very low and 
this may  impact on the efficiency of the  editing activity. Higher 
levels of human apoBlOO expression may result  in a  decrease  in 
the proportion of human  transcripts  that undergo  editing. 
Our observation that  the  human liver apoB mRNA synthe- 
sized by transgenic mice is extensively edited is in contrast to 
data originally reported by  Xiong et al. (171, which has subse- 
quently been retracted (33). It  appears  that a multicomponent 
is necessary for apoB mRNA editing (6-8). The simplest com- 
plex would  be one in which one subunit or protein recognizes 
and binds the apoBlOO mRNA and  another protein catalyzes 
the  deamination of cytidine 6666. The  site recognized by the 
mRNA-binding component has been identified as  an ll-nucleo- 
tide sequence  downstream from the  editing  site (34). This 11- 
nucleotide  sequence is conserved perfectly in five species that 
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B. M,M,,,l 2 3 4  5 6 
Human lTA- - m o r  
Mouse TAA - - 
CAAlCTA + -00 
Yo Edited  54  8  36 - - - 
C. M,M,,,l 2 3 4  5 6 
HumanTTA- * 
Mouse TAA - 
CAAlCTA- 
YO Edited  83  73 71 67 70 65 
FIG. 4. Primer  extension  analysis of transgenic  liver RNA. Total 
hepatic RNA from both  transgenic  and  non-transgenic mice livers  were 
amplified and analyzed by primer extension analysis. Panel A, the 
amplified products from 3 transgenic mice (lanes 1-31 and 3 control 
mice (lanes 4 6 )  were  size-fractionated on a 5% polyacrylamide  gel,  and 
the gel was  stained  with  ethidium bromide. Panels B and C,  a  primer 
extension assay was performed using RT-PCR-generated DNA frag- 
ments  amplified  employing  either  human-specific oligonucleotides 
(panel B, lanes 1-6) or mouse-specific oligonucleotides (panel C,  lanes 
1-6). As size  controls,  primer  extensive  products of synthetic RNA cor- 
responding  to  edited  human ( M h )  or mouse (Mn) were  used.  Human- 
specific oligonucleotides ( M h )  or mouse-specific oligonucleotides ( M m )  
were employed to  amplify  total  transgenic  mouse  hepatic RNA. Arrows 
a t  left of figure  designate  the expected position of non-edited (CMCTA) 
and  edited  mouse (TAA) and  human (TTA) extension  products, respec- 
tively. The  percentage of edited  template  was  determined  using  the 
Ambis-100 imaging  system  and  is given below each  lane. 
have been examined (35). Nevertheless, species-specific se- 
quence differences of apoBlOO substrates in flanking regions 
have  resulted  in  moderate differences in  editing efficiency in 
vitro. For example,  previous studies  have revealed that a 354- 
nucleotide rabbit apoBlOO RNA substrate  is edited 1.8 times 
more efficiently than a human apoBlOO template of similar 
length by a rabbit enterocyte extract (36). As demonstrated  in 
the  present  studies, apoB RNA editing in vivo also has limited 
species specificity. Endogenous mouse apoBlOO  mRNA was ed- 
ited about 1.6 times more efficiently than the human apoB 
RNA. Thus, our results of slightly  decreased editing efficiency 
of the human apoB transcript compared to the endogenous 
mouse transcript  agree well with results from previous in vitro 
experiments (36). Therefore, even though our results,  and those 
of previous investigations (36, 37) show that mRNA editing 
appears to be influenced by species-specific sequences flanking 
the binding and  editing  sites,  the  present  results indicate that 
Dansgenic Mice 
there  is no absolute species specificity to  the apoB mRNA ed- 
iting process. 
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